Abnormal aldolase level
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormal lactate dehydrogenase activity
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormality iris morphology
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Abnormality of retinal pigmentation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Abnormality of the voice
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Absence of septum pellucidum
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Absent reflex
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We used two MB cell line (D283-MED and MEB-Med8A) and a widely used glioblastoma cell line (U87MG) for comparison.
|
30943920 |
2019 |
Adult Glioblastoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
PomGnT1 enhances temozolomide resistance by activating epithelial-mesenchymal transition signaling in glioblastoma.
|
29048655 |
2017 |
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We used two MB cell line (D283-MED and MEB-Med8A) and a widely used glioblastoma cell line (U87MG) for comparison.
|
30943920 |
2019 |
Agenesis of corpus callosum
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
alpha-Dystroglycanopathies
|
0.330 |
Biomarker
|
disease |
BEFREE |
At present, of the six proteins involved on alpha-dystroglycanopathies, the function of the gene products is only known for POMT1, POMT2, and POMGnT1, all responsible for the O-mannosylglycan biosynthesis.
|
20816175 |
2010 |
alpha-Dystroglycanopathies
|
0.330 |
Biomarker
|
disease |
BEFREE |
The protein O-mannose beta-1,2-N-acetylglucosaminyltransferase 1 (POMGNT1) gene is one of 18 genes involved in the pathogenesis of α-dystroglycanopathies(α-DGPs) such as muscle-eye-brain disease (MEB).
|
28765568 |
2017 |
alpha-Dystroglycanopathies
|
0.330 |
Biomarker
|
disease |
CTD_human |
|
|
|
alpha-Dystroglycanopathies
|
0.330 |
Biomarker
|
disease |
BEFREE |
The secondary α-dystroglycanopathies usually present in infancy as congenital muscular dystrophies but may manifest later in childhood or adult life (limb-girdle muscular dystrophy (LGMD) 2I, LGMD2K, LGMD2M, LGMD2N, and LGMD2O).
|
21496628 |
2011 |
Anophthalmos
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Anteverted nostril
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Aplasia/Hypoplasia involving the skeletal musculature
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Aplasia/Hypoplasia of the cerebellum
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Aplasia/Hypoplasia of the corpus callosum
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Atrophic retina
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
Atypical scarring of skin
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
Autism Spectrum Disorders
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We apply whole-exome sequencing (WES) to ASD families enriched for inherited causes due to consanguinity and find familial ASD associated with biallelic mutations in disease genes (AMT, PEX7, SYNE1, VPS13B, PAH, and POMGNT1).
|
23352163 |
2013 |
Autosomal recessive retinitis pigmentosa
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
In our study, we have identified recessive mutations in POMGNT1, which encodes an essential component in O-mannosylation pathway, in three unrelated families with autosomal recessive retinitis pigmentosa (RP), but without extraocular involvement.
|
26908613 |
2016 |
Autosomal recessive retinitis pigmentosa
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We identified a novel mutation in POMGNT1 that causes nonsyndromic autosomal recessive retinitis pigmentosa, adding to the genetic heterogeneity of this retinal disease.
|
27391550 |
2016 |